Literature DB >> 3159749

Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks.

A L Barry, R J Fass, J P Anhalt, H C Neu, C Thornsberry, R C Tilton, B G Painter, J A Washington.   

Abstract

Evaluations of 5-microgram ciprofloxacin disk diffusion susceptibility tests were performed independently by seven different investigators. The results of the separate tests were combined to increase the number of resistant strains in the challenge set of microorganisms. Based on data with 2,652 isolates, the following interpretive breakpoints are tentatively proposed for use in ongoing clinical trials of ciprofloxacin: less than or equal to 15 mm, resistant (MIC greater than 2.0 micrograms/ml); 16 to 20 mm, intermediate (1.0 less than MIC less than or equal to 2.0 micrograms/ml); and greater than or equal to 21 mm, susceptible (MIC less than or equal to 1.0 micrograms/ml). Disk tests with Streptococcus spp. and with Pseudomonas maltophilia were not reliable; other microorganisms were accurately categorized by the disk diffusion test.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159749      PMCID: PMC271810          DOI: 10.1128/jcm.21.6.880-883.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

2.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

3.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller; A Iliffe
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

4.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

5.  Dose- and sex-independent disposition of ciprofloxacin.

Authors:  D Höffler; A Dalhoff; W Gau; D Beermann; A Michl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

6.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

7.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

8.  Diffusion of ciprofloxacin into prostatic fluid.

Authors:  A Dalhoff; W Weidner
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

View more
  18 in total

1.  Comparison of three dosage regimens of ciprofloxacin in urinary tract infections.

Authors:  V Prát; M Horcicková; K Matousovic; M Hatala
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

2.  Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019 Enterobacteriaceae CLSI Breakpoints.

Authors:  Romney M Humphries; Janet A Hindler; Keith Shaffer; Shelley A Campeau
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

3.  Interpretive criteria for the agar diffusion susceptibility test with ofloxacin.

Authors:  H Grimm
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Antimicrobic susceptibility and plasmid profile analysis as identity tests for multiple blood isolates of coagulase-negative staphylococci.

Authors:  A I Hartstein; M A Valvano; V H Morthland; P C Fuchs; S A Potter; J H Crosa
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

5.  Comparison of the Cobas-Bact five-hour susceptibility testing system with the NCCLS agar diffusion and dilution methods.

Authors:  J Wüst; W Heizmann; U Hardegger; B Manncke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

6.  Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics.

Authors:  H Stuht; H Lode; P Koeppe; K L Rost; T Schaberg
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

7.  Evaluation of four newer antimicrobial agents in the Avantage susceptibility test system.

Authors:  D N Wright; J M Matsen; J R DiPersio; M Kirk; B Saxon; S M Ficorilli; H J Spencer
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

8.  Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

10.  Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.